Treatment Strategies

Kaneko, K. (2018). Negative symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning. Yonago Acta Med, 61, 91–102.Google Scholar

Dack, C., Ross, J., Papadopoulos, C., et al. (2013). A review and meta-analysis of the patient factors associated with psychiatric in-patient aggression. Acta Psychiatr Scand, 127, 255–268.CrossRef Google Scholar PubMed

Quanbeck, C. D., McDermott, B. E., Lam, J., et al. (2007). Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv, 58, 521–528.CrossRef Google Scholar PubMed

Stahl, S. M., Morrissette, D. A., Cummings, M., et al. (2014). California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr, 19, 449–465.Google Scholar

Merritt, K., McGuire, P., Egerton, A. (2013). Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry, 4, 151.CrossRef Google Scholar PubMed

Howes, O. D., McCutcheon, R., Agid, O., et al. (2017). Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174, 216–229.CrossRef Google Scholar

Maust, D. T., Kim, H. M., Seyfried, L. S., et al. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry, 72, 438–445.CrossRef Google Scholar PubMed

Galling, B., Roldan, A., Hagi, K., et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry, 16, 77–89.CrossRef Google Scholar PubMed

Nucifora, F. C. Jr., Woznica, E., Lee, B. J., et al. (2018). Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis, 131, 104–257.Google Scholar PubMed

Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789–796.Google Scholar

Stroup, T. S., Gerhard, T., Crystal, S., et al. (2016). Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry, 173, 166–173.Google Scholar

Yoshimura, B., Yada, Y., So, R., et al. (2017). The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res, 250, 65–70.CrossRef Google Scholar PubMed

Ogloff, J. R., Daffern, M. (2006). The dynamic appraisal of situational aggression: an instrument to assess risk for imminent aggression in psychiatric inpatients. Behav Sci Law, 24, 799–813.CrossRef Google Scholar PubMed

Hankin, C. S., Bronstone, A., Koran, L. M. (2011). Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment. J Psychiatr Pract, 17, 170–185.CrossRef Google Scholar PubMed

Vaaler, A. E., Iversen, V. C., Morken, G., et al. (2011). Short-term prediction of threatening and violent behaviour in an Acute Psychiatric Intensive Care Unit based on patient and environment characteristics. BMC Psychiatry, 11, 44.Google Scholar

Volavka, J., Citrome, L. (2011). Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull, 37, 921–929.Google Scholar

Joshi, A., Krishnamurthy, V. B., Purichia, H., et al. (2012). “What’s in a name?” Delirium by any other name would be as deadly. A review of the nature of delirium consultations. J Psychiatr Pract, 18, 413–418.CrossRef Google Scholar

Ruberg, S. J., Chen, L., Stauffer, V., et al. (2011). Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry, 11, 23.Google Scholar

Lopez, L. V., Kane, J. M. (2013). Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res, 147, 368–374.CrossRef Google Scholar PubMed

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.Google Scholar

Siskind, D., Siskind, V., Kisely, S. (2017). Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry, 62, 772–777.Google Scholar

Lally, J., Tully, J., Robertson, D., et al. (2016). Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res, 171, 215–224.CrossRef Google Scholar PubMed

Stein-Parbury, J., Reid, K., Smith, N., et al. (2008). Use of pro re nata medications in acute inpatient care. Aust N Z J Psychiatry, 42, 283–292.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry, 81(3), 19CS13169.Google Scholar

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.CrossRef Google Scholar PubMed

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.CrossRef Google Scholar PubMed

Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 1138–1143.CrossRef Google Scholar PubMed

Meyer, J. M. (2018). Gilman: The Pharmacological Basis of Therapeutics. Pharmacotherapy of Psychosis and Mania. New York: McGraw-Hill.Google Scholar

Letmaier, M., Painold, A., Holl, A. K., et al. (2012). Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol, 15, 739–748.CrossRef Google Scholar PubMed

Kim, Y-S., Kim, D. W., Jung, K-H., et al. (2014). Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure, 23, 208–212.Google Scholar

Gottfried, E. D., Christopher, S. C. (2017). Mental disorders among criminal offenders: a review of the literature. J Correct Health Care, 23, 336–346.CrossRef Google Scholar PubMed

Cummings, M. A., Proctor, G. J., Arias, A. W. (2020). Dopamine antagonist antipsychotics in diverted forensic populations. CNS Spectr, 25, 128–135.Google Scholar

de Haan, L., Lavalaye, J., van Bruggen, M., et al. (2004). Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry, 49, 290–296.Google Scholar

Garcia, S., Martinez-Cengotitabengoa, M., Lopez-Zurbano, S., et al. (2016). Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol, 36, 355–371.CrossRef Google Scholar PubMed

Ostuzzi, G., Barbui, C. (2016). Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study. Epidemiol Psychiatr Sci, 25, 21–23.Google Scholar

Stevens, G. L., Dawson, G., Zummo, J. (2016). Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry, 10, 365–377.CrossRef Google Scholar PubMed

Mohr, P., Knytl, P., Vorackova, V., et al. (2017). Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. Int J Clin Pract, 71, 1–7.CrossRef Google Scholar PubMed

Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., et al. (2018). Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res, 197, 274–280.CrossRef Google Scholar

Marcus, S. C., Zummo, J., Pettit, A. R., et al. (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm, 21, 754–768.Google Scholar

Cummings, M. A., Proctor, G. J., Arias, A. W. (2019). Dopamine antagonist antipsychotics in diverted forensic populations. CNS Spectr, in press. doi: 10.1017/S1092852919000841CrossRef Google Scholar

Meyer, J. M. (2017). Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr, 22, 14–28.CrossRef Google Scholar PubMed

Lieberman, J. A. (2004). Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 18, 251–267.Google Scholar

Stip, E., Tourjman, V. (2010). Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther, 32, S3–20.Google Scholar

Park, E. J., Amatya, S., Kim, M. S., et al. (2013). Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res, 36, 651–659.CrossRef Google Scholar PubMed

Spanarello, S., La Ferla, T. (2014). The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol, 9, 310–317.Google Scholar

Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar

Nyberg, S., Dencker, S. J., Malm, U., et al. (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol, 1, 95–101.Google Scholar

Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol, 37, 289–295.CrossRef Google Scholar PubMed

Meyer, J. M. (2019). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25(2), 136–144.CrossRef Google Scholar PubMed

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.Google Scholar

Meyer, J. M. (2019). The Clozapine Handbook. Stahl’s Handbooks. New York: Cambridge University Press.Google Scholar

Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789–796.CrossRef Google Scholar PubMed

Howes, O. D., McCutcheon, R., Agid, O., et al. (2016). Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174, 216–229.Google Scholar

Galling, B., Roldan, A., Hagi, K., et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry, 16, 77–89.Google Scholar

Stroup, T. S., Gerhard, T., Crystal, S., et al. (2015). Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry, 173, 166–173.Google Scholar

Siskind, D., Siskind, V., Kisely, S. (2017). Clozapine Response Rates among People with Treatment-resistant Schizophrenia: Data from a Systematic Review and Meta-analysis. Los Angeles, CA: SAGE Publications.Google Scholar

Yoshimura, B., Yada, Y., So, R., et al. (2017). The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res, 250, 65–70.Google Scholar

Meltzer, H. Y., Alphs, L., Green, A. I., et al. (2003). Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry, 60, 82–91.Google Scholar

Quanbeck, C. D., McDermott, B. E., Lam, J., et al. (2007). Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv, 58, 521–528.Google Scholar

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.Google Scholar

Fazel, S., Gulati, G., Linsell, L., et al. (2009). Schizophrenia and violence: systematic review and meta-analysis. PLoS Med, 6, e1000120.Google Scholar

Fazel, S., Långström, N., Hjern, A., et al. (2009). Schizophrenia, substance abuse, and violent crime. JAMA, 301, 2016–2023.Google Scholar

Krakowski, M. I., Czobor, P., Citrome, L., et al. (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, 63, 622–629.Google Scholar

Frogley, C., Taylor, D., Dickens, G., et al. (2012). A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol, 15, 1351–1371.CrossRef Google Scholar PubMed

Vanderwaal, F. M. (2015). Impact of motivational interviewing on medication adherence in schizophrenia. Issues Ment Health Nurs, 36, 900–904.CrossRef Google Scholar PubMed

Reimer, J., Kuhn, J., Wietfeld, R., et al. (2019). Motivational interviewing: a possibility for doctor-patient communication in schizophrenia? Der Nervenarzt, 90(11), 1144–1153.Google Scholar

Kaneko, K. (2018). Negative symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning. Yonago Acta Med, 61, 91–102.Google Scholar

Liu, J., Chan, T. C. T., Chong, S. A., et al. (2019). Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. Early Interv Psychiatry, 14(6), 691–697.CrossRef Google Scholar PubMed

Barch, D. M., Pagliaccio, D., Luking, K. (2016). Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia. Curr Top Behav Neurosci, 27, 411–449.Google Scholar

Sher, L., Kahn, R. S. (2019). Suicide in schizophrenia: an educational overview. Medicina (Kaunas), 55(7), 361.Google Scholar

Pompili, M., Orsolini, L., Lamis, D. A., et al. (2017). Suicide prevention in schizophrenia: do long-acting injectable antipsychotics (LAIs) have a role? CNS Neurol Disord Drug Targets, 16, 454–462.Google Scholar

Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., et al. (2018). Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res, 197, 274–280.Google Scholar

Ertugrul, A. (2002). Clozapine and suicide. Am J Psychiatry, 159, 323; author reply 324.Google Scholar

Kane, J. M. (2017). Clozapine reduces all-cause mortality. Am J Psychiatry, 174, 920–921.Google Scholar

Roberts, E., Cipriani, A., Geddes, J. R., et al. (2017). The evidence for lithium in suicide prevention. Br J Psychiatry, 211, 396.CrossRef Google Scholar PubMed

Kanehisa, M., Terao, T., Shiotsuki, I., et al. (2017). Serum lithium levels and suicide attempts: a case-controlled comparison in lithium therapy-naive individuals. Psychopharmacology (Berl), 234, 3335–3342.Google Scholar

Deslauriers, J., Belleville, K., Beaudet, N., et al. (2016). A two-hit model of suicide-trait-related behaviors in the context of a schizophrenia-like phenotype: distinct effects of lithium chloride and clozapine. Physiol Behav, 156, 48–58.Google Scholar

Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med, 356, 1711–1722.Google Scholar

Gitlin, M. J. (2018). Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord, 6, 25.Google Scholar

Cheniaux, E., Nardi, A. E. (2019). Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf, 18, 893–913.Google Scholar

Marx, W., Moseley, G., Berk, M., et al. (2017). Nutritional psychiatry: the present state of the evidence. Proc Nutr Soc, 76, 427–436.CrossRef Google Scholar PubMed

Dougall, N., Maayan, N., Soares-Weiser, K., et al. (2015). Transcranial magnetic stimulation for schizophrenia. Schizophr Bull, 41, 1220–1222.Google Scholar

Moffa, A. H., Brunoni, A. R., Nikolin, S., et al. (2018). Transcranial direct current stimulation in psychiatric disorders: a comprehensive review. Psychiatr Clin North Am, 41, 447–463.Google Scholar

Pompili, M., Lester, D., Dominici, G., et al. (2013). Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res, 146, 1–9.Google Scholar

Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476–483.Google Scholar

Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., et al. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry, 173, 600–606.Google Scholar

Rubio, J. M., Correll, C. U. (2017). Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. Evid Based Ment Health, 20, e6.Google Scholar

Loebel, A., Xu, J., Hsu, J., et al. (2015). The development of lurasidone for bipolar depression. Ann N Y Acad Sci, 1358, 95–104.Google Scholar

Post, R. M. (2016). Treatment of bipolar depression: evolving recommendations. Psychiatr Clin North Am, 39, 11–33.CrossRef Google Scholar PubMed

Szmulewicz, A. G., Angriman, F., Samame, C., et al. (2017). Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand, 135, 527–538.Google Scholar

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.Google Scholar

Nolan, K. A., Czobor, P., Roy, B. B., et al. (2003). Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr Serv, 54, 1012–1016.Google Scholar

Quanbeck, C. D., McDermott, B. E., Lam, J., et al. (2007). Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv, 58, 521–528.Google Scholar

Stahl, S. M., Morrissette, D. A., Cummings, M., et al. (2014). California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr, 19, 449–465.Google Scholar

Dardashti, L., O’Day, J., Barsom, M., et al. (2015). Illustrative cases to support the Cal-VAT guidelines. CNS Spectr, 20, 311–318.Google Scholar

Morrissette, D. A., Stahl, S. M. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr, 19, 439–448.Google Scholar

Nielsen, J., Dahm, M., Lublin, H., et al. (2010). Psychiatrists’ attitude towards and knowledge of clozapine treatment. Psychopharmacol, 24, 965–971.CrossRef Google Scholar PubMed

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.CrossRef Google Scholar PubMed

McCutcheon, R., Beck, K., Bloomfield, M. A., et al. (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol, 29, 892–897.Google Scholar

Meyer, J. M. (2019). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25(2), 1–9.Google Scholar

Keckich, W. (1978). Neuroleptics: violence as a manifestation of akathisia. JAMA, 240, 2185.Google Scholar

Schulte, J. (1985). Homicide and suicide associated with akathisia and haloperidol. Am J Forensic Psychiatry, 6, 3–7.Google Scholar

Galynker, I., Nazarian, D. (1997). Akathisia as violence. J Clin Psychiatry, 58, 31–32.Google Scholar

Stubbs, J. H., Hutchins, D. A., Mountjoy, C. Q. (2000). Relationship of akathisia to aggressive and self-injurious behaviour: a prevalence study in a UK tertiary referral centre. Int J Psychiatry Clin Pract, 4, 319–325.Google Scholar

Antosik-Wojcinska, A., Stefanowski, B., Swiecicki, L. (2015). Efficacy and safety of antidepressant’s use in the treatment of depressive episodes in bipolar disorder – review of research. Psychiatr Pol, 49, 1223–1239.Google Scholar

Lähteenvuo, M., Tanskanen, A., Taipale, H., et al. (2018). Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry, 75, 347–355.Google Scholar

Volz, A., Khorsand, V., Gillies, D., et al. (2007). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google Scholar

Dold, M., Li, C., Tardy, M., et al. (2012). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google Scholar

Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476–483.Google Scholar

Dold, M., Li, C., Gillies, D., et al. (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol, 23, 1023–1033.Google Scholar

Gillies, D., Sampson, S., Beck, A., et al. (2013). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, 9, CD003079.Google Scholar

Dodds, T. J. (2017). Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord, 19(2).CrossRef Google Scholar

Takeuchi, H., Remington, G. (2013). A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl), 228, 175–185.CrossRef Google Scholar PubMed

Stahl, S. (2014). Antipsychotic agents. In Stahl’s Essential Psychopharmacology (ed.). New York: Cambridge University Press, p. 169.Google Scholar

Meyer, J. M., Stahl, S. M. (2019). The Clozapine Handbook. New York: Cambridge University Press.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R., and Knollmann, B. C. (eds.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Baldessarini, R. J., Tondo, L., Vazquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Mol Psychiatry, 24, 198–217.Google Scholar

Post, R. M., Ketter, T. A., Uhde, T., et al. (2007). Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs, 21, 47–71.Google Scholar

Zaccara, G., Perucca, E. (2014). Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord, 16, 409–431.Google Scholar

Yatham, L. N., Beaulieu, S., Schaffer, A., et al. (2016). Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry, 21, 1050–1056.Google Scholar

Leucht, S., Helfer, B., Dold, M., et al. (2015). Lithium for schizophrenia. Cochrane Database Syst Rev, 10, CD003834.Google Scholar

Jochim, J., Rifkin-Zybutz, R. P., Geddes, J., et al. (2019). Valproate for acute mania. Cochrane Database Syst Rev, 10, CD004052.Google Scholar PubMed

Vasudev, A., Macritchie, K., Watson, S., et al. (2008). Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev, 10, CD005171.Google Scholar

Vasudev, A., Macritchie, K., Vasudev, K., et al. (2011). Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev, 10, CD004857.Google Scholar

Kim, Y. S., Kim, D. W., Jung, K. H., et al. (2014). Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure, 23, 208–212.CrossRef Google Scholar PubMed

Malhi, G. S., Tanious, M. (2011). Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs, 25, 289–298.Google Scholar

Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacology, 41, 1138–1143.Google Scholar

Gerhard, T., Devanand, D. P., Huang, C., et al. (2015). Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry, 207, 46–51.Google Scholar

Hayes, J. F., Pitman, A., Marston, L., et al. (2016). Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study. JAMA Psychiatry, 73, 630–637.Google Scholar

Song, J., Sjolander, A., Joas, E., et al. (2017). Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry, 174, 795–802.Google Scholar

Van Gestel, H., Franke, K., Petite, J., et al. (2019). Brain age in bipolar disorders: effects of lithium treatment. Aust N Z J Psychiatry, 53(12), 1179–1188.CrossRef Google Scholar PubMed

Hirschfeld, R. M., Allen, M. H., McEvoy, J. P., et al. (1999). Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry, 60, 815–818.Google Scholar

Wingard, L., Brandt, L., Boden, R., et al. (2019). Monotherapy vs. combination therapy for post mania maintenance treatment: a population based cohort study. Eur Neuropsychopharmacology, pii, S0924-977X(19)30234-2. doi: 10.1016/j.euroneuro.2019.04.003Google Scholar

Remington, G., Teo, C., Mann, S., et al. (2013). Examining levels of antipsychotic adherence to better understand nonadherence. J Clin Psychopharmacol, 33, 261–263.Google Scholar

Murru, A., Pacchiarotti, I., Amann, B. L., et al. (2013). Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord, 151, 1003–1008.Google Scholar

Even, C., Thuile, J., Kalck-Stern, M., et al. (2010). Psychoeducation for patients with bipolar disorder receiving lithium: short and long term impact on locus of control and knowledge about lithium. J Affect Disord, 123, 299–302.Google Scholar

Butler, M., Urosevic, S., Desai, P., et al. (2018). AHRQ comparative effectiveness reviews. In Treatment for Bipolar Disorder in Adults: A Systematic Review (eds.). Rockville, MD: Agency for Healthcare Research and Quality.Google Scholar

Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136–144.Google Scholar

Murru, A., Pacchiarotti, I., Nivoli, A. M., et al. (2011). What we know and what we don’t know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol, 21, 680–690.Google Scholar

Vieta, E. (2010). Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. J Clin Psychiatry, 71 Suppl. 2, 14–19.Google Scholar

Koola, M. M., Fawcett, J. A., Kelly, D. L. (2011). Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care. J Nerv Ment Dis, 199, 989–990.Google Scholar

Bartova, L., Papageorgiou, K., Milenkovic, I., et al. (2018). Rapid antidepressant effect of S-ketamine in schizophrenia. Eur Neuropsychopharmacol, 28, 980–982.Google Scholar

Tundo, A., de Filippis, R., De Crescenzo, F. (2019). Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr Scand, 140, 116–125.Google Scholar

Kelleher, J. P., Centorrino, F., Huxley, N. A., et al. (2012). Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol, 22, 415–418.Google Scholar

Eli Lilly and Company (2019). Zyprexa Package Insert. Indianapolis.Google Scholar

Pfizer Inc. (2018). Geodon Package Insert. New York, New York.Google Scholar

Kook, K. A., Stimmel, G. L., Wilkins, J. N., et al. (1985). Accuracy and safety of a priori lithium loading. J Clin Psychiatry, 46, 49–51.Google Scholar PubMed

Reed, R. C., Dutta, S. (2006). Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? Ther Drug Monit, 28, 413–418.Google Scholar

Meyer, J. M. (2019). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, in press. doi: 10.1017/S1092852919000865CrossRef Google Scholar

Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol, 37, 289–295.Google Scholar

Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase i study and a population pharmacokinetic model. CNS Drugs, 31, 617–624.CrossRef Google Scholar

Temmingh, H., Stein, D. J. (2015). Anxiety in patients with schizophrenia: epidemiology and management. CNS Drugs, 29, 819–832.CrossRef Google Scholar PubMed

Bosanac, P., Mancuso, S. G., Castle, D. J. (2016). Anxiety symptoms in psychotic disorders: results from the Second Australian National Mental Health Survey. Clin Schizophr Relat Psychoses, 10, 93–100.Google Scholar

Van der Heiden, W., Konnecke, R., Maurer, K., et al. (2005). Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci, 255, 174–184.Google Scholar

Wang, D., Gopal, S., Baker, S., et al. (2018). Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophr, 4, 10.Google Scholar

Velligan, D., Carpenter, W., Waters, H. C., et al. (2018). Relapse Risk Assessment for Schizophrenia Patients (RASP): a new self-report screening tool. Clin Schizophr Relat Psychoses, 11, 224–235.Google Scholar

Lohr, J. B., Eidt, C. A., Abdulrazzaq Alfaraj, A., et al. (2015). The clinical challenges of akathisia. CNS Spectr, 20 Suppl. 1, 1–14; quiz 15–16.Google Scholar

Porcelli, S., Bianchini, O., De Girolamo, G., et al. (2016). Clinical factors related to schizophrenia relapse. Int J Psychiatry Clin Pract, 20, 54–69.Google Scholar

Salem, H., Nagpal, C., Pigott, T., et al. (2017). Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol, 15, 789–798.Google Scholar

Shear, M. K., Frances, A., Weiden, P. (1983). Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol, 3, 235–236.Google Scholar

Drake, R. E., Ehrlich, J. (1985). Suicide attempts associated with akathisia. Am J Psychiatry, 142, 499–501.Google Scholar PubMed

Sachdev, P., Loneragan, C. (1992). Reported association of akathisia with suicide. J Nerv Ment Dis, 180, 339.CrossRef Google Scholar PubMed

Lima, A. R., Soares-Weiser, K., Bacaltchuk, J., et al. (2002). Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev, 1999(1), CD001950.Google Scholar

Lima, A. R., Bacalcthuk, J., Barnes, T. R., et al. (2004). Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev, 2004, CD001946.Google Scholar

Praharaj, S. K., Kongasseri, S., Behere, R. V., et al. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol, 5, 307–313.CrossRef Google Scholar PubMed

Lima, A. R., Weiser, K. V., Bacaltchuk, J., et al. (2004). Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev, 2004, CD003727.Google Scholar

Vinogradov, S., Fisher, M., Warm, H., et al. (2009). The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry, 166, 1055–1062.CrossRef Google Scholar PubMed

Borghans, L., Sambeth, A., Blokland, A. (2020). Biperiden selectively impairs verbal episodic memory in a dose- and time-dependent manner in healthy subjects. J Clin Psychopharmacol, 40, 30–37.Google Scholar

Tiihonen, J., Suokas, J. T., Suvisaari, J. M., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, 69, 476–483.Google Scholar

Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., et al. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry, 173, 600–606.Google Scholar

Young, S., Pfaff, D., Lewandowski, K. E., et al. (2013). Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder. Psychopathology, 46, 176–185.Google Scholar

Serafini, G., Gonda, X., Aguglia, A., et al. (2019). Bipolar subtypes and their clinical correlates in a sample of 391 bipolar individuals. Psychiatry Res, 281, 112528.Google Scholar

Leucht, S., Helfer, B., Dold, M., et al. (2015). Lithium for schizophrenia. Cochrane Database Syst Rev, 2015, CD003834.Google Scholar

Dold, M., Li, C., Tardy, M., et al. (2012). Benzodiazepines for schizophrenia. Cochrane Database Syst Rev, 11, CD006391.Google Scholar

Zaman, H., Sampson, S. J., Beck, A. L., et al. (2017). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev, 12, CD003079.Google Scholar

Dold, M., Li, C., Gillies, D., et al. (2013). Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol, 23, 1023–1033.Google Scholar

Murru, A., Pacchiarotti, I., Nivoli, A. M., et al. (2011). What we know and what we don’t know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol, 21, 680–690.Google Scholar

Tezenas du Montcel, C., Pelissolo, A., Schurhoff, F., et al. (2019). Obsessive-compulsive symptoms in schizophrenia: an up-to-date review of literature. Curr Psychiatry Rep, 21, 64.CrossRef Google Scholar PubMed

Scotti-Muzzi, E., Saide, O. L. (2017). Schizo-obsessive spectrum disorders: an update. CNS Spectr, 22, 258–272.Google Scholar

Kuhlman, S. J., Craig, L. M., Duffy, J. F. (2018). Introduction to chronobiology. Cold Spring Harb Perspect Biol, 10(9), a033613.Google Scholar

Capezuti, E. A. (2016). The power and importance of sleep. Geriatr Nurs, 37, 487–488.Google Scholar

Chan, M. S., Chung, K. F., Yung, K. P., et al. (2017). Sleep in schizophrenia: a systematic review and meta-analysis of polysomnographic findings in case-control studies. Sleep Med Rev, 32, 69–84.Google Scholar

Cosgrave, J., Wulff, K., Gehrman, P. (2018). Sleep, circadian rhythms, and schizophrenia: where we are and where we need to go. Curr Opin Psychiatry, 31, 176–182.Google Scholar

Altena, E., Micoulaud-Franchi, J. A., Geoffroy, P. A., et al. (2016). The bidirectional relation between emotional reactivity and sleep: from disruption to recovery. Behav Neurosci, 130, 336–350.Google Scholar

Bollu, P. C., Kaur, H. (2019). Sleep medicine: insomnia and sleep. Mo Med, 116, 68–75.Google Scholar

Sargant, W. (1958). Sedatives and tranquillizers. I. Br Med J, 2, 1031–1032.Google Scholar

Ashton, H. (1994). Guidelines for the rational use of benzodiazepines. When and what to use. Drugs, 48, 25–40.CrossRef Google Scholar PubMed

de la Iglesia-Larrad, J. I., Barral, C., Casado-Espada, N. M., et al. (2019). Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: a review of the literature. Psychiatry Res, 284(1), 12660.Google Scholar

Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., et al. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry, 173, 600–606.Google Scholar

Matheson, E., Hainer, B. L. (2017). Insomnia: pharmacologic therapy. Am Fam Physician, 96, 29–35.Google Scholar

Monti, J. M., Monti, D. (2005). Sleep disturbance in schizophrenia. Int Rev Psychiatry, 17, 247–253.Google Scholar

Pavlova, M. (2017). Circadian rhythm sleep-wake disorders. Continuum (Minneap Minn), 23, 1051–1063.Google Scholar

Liblau, R. S., Vassalli, A., Seifinejad, A., et al. (2015). Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol, 14, 318–328.Google Scholar

Coleman, P. J., Gotter, A. L., Herring, W. J., et al. (2017). The discovery of suvorexant, the first orexin receptor drug for insomnia. Annu Rev Pharmacol Toxicol, 57, 509–533.CrossRef Google Scholar PubMed

Kuriyama, A., Tabata, H. (2017). Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis. Sleep Med Rev, 35, 1–7.Google Scholar

Herring, W. J., Connor, K. M., Ivgy-May, N., et al. (2016). Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry, 79, 136–148.Google Scholar

Murphy, P., Moline, M., Mayleben, D., et al. (2017). Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med, 13, 1289–1299.Google Scholar

Dujardin, S., Pijpers, A., Pevernagie, D. (2018). Prescription drugs used in insomnia. Sleep Med Clin, 13, 169–182.Google Scholar

Yanai, K., Rogala, B., Chugh, K., et al. (2012). Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin, 28, 623–642.Google Scholar

Antosik-Wojcinska, A. Z., Stefanowski, B., Swiecicki, L. (2015). Efficacy and safety of antidepressant’s use in the treatment of depressive episodes in bipolar disorder – review of research. Psychiatr Pol, 49, 1223–1239.Google Scholar

Mendelson, W. B. (2005). A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry, 66, 469–476.Google Scholar

Chew, M. L., Mulsant, B. H., Pollock, B. G., et al. (2008). Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc, 56, 1333–1341.Google Scholar

Rosenberg, R. P. (2006). Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry, 18, 49–56.Google Scholar

Zammit, G. K., Corser, B., Doghramji, K., et al. (2006). Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med, 2, 417–423.Google Scholar

Huedo-Medina, T. B., Kirsch, I., Middlemass, J., et al. (2012). Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ, 345, e8343.Google Scholar

Atkin, T., Comai, S., Gobbi, G. (2018). Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev, 70, 197–245.Google Scholar

Williams, W. P. 3rd, McLin, D. E. 3rd, Dressman, M. A., et al. (2016). Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy, 36, 1028–1041.Google Scholar

Liu, J., Zhong, R., Xiong, W., et al. (2017). Melatonin increases reactive aggression in humans. Psychopharmacology (Berl), 234, 2971–2978.Google Scholar

Tordjman, S., Chokron, S., Delorme, R., et al. (2017). Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol, 15, 434–443.Google Scholar

Asnis, G. M., Thomas, M., Henderson, M. A. (2015). Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci, 17(1), 50.Google Scholar

Joober, R., Cole, K., Tabbane, K., et al. (2017). An algorithmic approach to the management of insomnia in patients with schizophrenia. Ann Clin Psychiatry, 29, 133–144.Google Scholar

Kelleher, I., Connor, D., Clarke, M. C., et al. (2012). Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med, 42, 1857–1863.Google Scholar

Maloney, A. E., Yakutis, L. J., Frazier, J. A. (2012). Empirical evidence for psychopharmacologic treatment in early-onset psychosis and schizophrenia. Child Adolesc Psychiatr Clin, 21, 885–909.Google Scholar

McClellan, J., Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry, 52, 976–990.Google Scholar

Sikich, L. (2013). Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents. Child Adolesc Psychiatr Clin, 22, 655–673.Google Scholar

McClellan, J. (2018). Psychosis in children and adolescents. J Am Acad Child Adolesc Psychiatry, 57, 308–312.Google Scholar

Reichenberg, A., Caspi, A., Harrington, H., et al. (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry, 167, 160–169.Google Scholar

Ross, R. G. (2008). New findings on antipsychotic use in children and adolescents with schizophrenia spectrum disorders. Am J Psychiatry, 165(11), 1369–1372.Google Scholar

Rapoport, J. L., Gogtay, N. (2011). Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci, 29, 251–258.CrossRef Google Scholar PubMed

Penttilä, J., Paillére-Martinot, M-L., Martinot, J-L., et al. (2008). Global and temporal cortical folding in patients with early-onset schizophrenia. J Am Acad Child Adolesc Psychiatry, 47, 1125–1132.Google Scholar

Cornblatt, B. A., Lencz, T., Smith, C. W., et al. (2007). Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry, 64(4), 546–557.Google Scholar

Amminger, G. P., Schäfer, M. R., Papageorgiou, K., et al. (2010). Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry, 67, 146–154.Google Scholar

McGorry, P. D., Nelson, B., Markulev, C., et al. (2017). Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry, 74, 19–27.Google Scholar

Cannon, T. D., Cadenhead, K., Cornblatt, B., et al. (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry, 65, 28–37.Google Scholar

Ienciu, M., Romos¸an, F., Bredicean, C., et al. (2010). First episode psychosis and treatment delay – causes and consequences. Psychiatria Danubina, 22, 540–543.Google Scholar

Rubio, J. M., Sanjuán, J., Flórez-Salamanca, L., et al. (2012). Examining the course of hallucinatory experiences in children and adolescents: a systematic review. Schizophr Res, 138, 248–254.Google Scholar

Norman, R. M., Mallal, A. K., Manchanda, R., et al. (2007). Does treatment delay predict occupational functioning in first-episode psychosis? Schizophr Res, 91, 259–262.Google Scholar

Poulton, R., Caspi, A., Moffitt, T. E., et al. (2000). Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry, 57, 1053–1058.CrossRef Google Scholar PubMed

Robins, L. N., Helzer, J. E., Croughan, J., et al. (1981). National Institute of Mental Health diagnostic interview schedule: its history, characteristics, and validity. Arch Gen Psychiatry, 38, 381–389.Google Scholar

Barrera, M., Garrison-Jones, C. V. (1988). Properties of the Beck Depression Inventory as a screening instrument for adolescent depression. J Abnorm Child Psychol, 16, 263–273.Google Scholar

Jellinek, M. S., Murphy, J. M., Robinson, J., et al. (1988). Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction. J Pediatrics, 112, 201–209.Google Scholar

Werry, J. S., McClellan, J. M., Chard, L. (1991). Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. J Am Acad Child Adolesc Psychiatry, 30, 457–465.Google Scholar

Carlson, G. A., Fennig, S., Bromet, E. J. (1994). The confusion between bipolar disorder and schizophrenia in youth: where does it stand in the 1990s? J Am Acad Child Adolesc Psychiatry, 33, 453–460.Google Scholar

Kaufman, J., Birmaher, B., Brent, D., et al. (1997). Schedule for affective disorders and schizophrenia for school-age children – present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36, 980–988.Google Scholar

Conners, C. K., Sitarenios, G., Parker, J. D., et al. (1998). The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol, 26, 257–268.Google Scholar

Angold, A., Costello, E. J. (2000). The child and adolescent psychiatric assessment (CAPA). J Am Acad Child Adolesc Psychiatry, 39, 39–48.Google Scholar

Muris, P., Schmidt, H., Merckelbach, H. (2000). Correlations among two self-report questionnaires for measuring DSM-defined anxiety disorder symptoms in children: The Screen for Child Anxiety Related Emotional Disorders and the Spence Children’s Anxiety Scale. Pers Individ Differ, 28, 333–346.Google Scholar

Geller, B., Zimerman, B., Williams, M., et al. (2001). Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. J Am Acad Child Adolesc Psychiatry, 40, 450–455.Google Scholar

Lachar, D., Randle, S. L., Harper, R. A., et al. (2001). The brief psychiatric rating scale for children (BPRS-C): validity and reliability of an anchored version. J Am Acad Child Adolesc Psychiatry, 40, 333–340.Google Scholar

Gracious, B. L., Youngstrom, E. A., Findling, R. L., et al. (2002). Discriminative validity of a parent version of the Young Mania Rating Scale. J Am Acad Child Adolesc Psychiatry, 41, 1350–1359.Google Scholar

Group, R. U. o. P. P. A. S. (2002). The pediatric anxiety rating scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry, 41, 1061–1069.Google Scholar

Knight, J. R., Sherritt, L., Shrier, L. A., et al. (2002). Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med, 156, 607–614.Google Scholar

Kroenke, K., Spitzer, R. L. (2002). The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann, 32, 509–515.Google Scholar

Mohamadesmaiel, E., Alipour, A. (2002). A preliminary study on the reliability, validity and cut off points of the disorders of Children Symptom Inventory-4 (CSI-4). J Except Child, 2, 239–254.Google Scholar

Brooks, S. J., Krulewicz, S. P., Kutcher, S. (2003). The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial. J Child Adolesc Psychopharmacol, 13, 337–349.Google Scholar

Pavuluri, M. N., Herbener, E. S., Sweeney, J. A. (2004). Psychotic symptoms in pediatric bipolar disorder. J Affect Disord, 80, 19–28.Google Scholar

Timbremont, B., Braet, C., Dreessen, L. (2004). Assessing depression in youth: relation between the Children’s Depression Inventory and a structured interview. J Clin Child Adolesc Psychol, 33, 149–157.CrossRef Google Scholar PubMed

III Hale, W. W., Raaijmakers, Q., Muris, P., et al. (2005). Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED) in the general adolescent population. J Am Acad Child Adolesc Psychiatry, 44, 283–290.Google Scholar

Perrin, S., Meiser-Stedman, R., Smith, P. (2005). The Children’s Revised Impact of Event Scale (CRIES): validity as a screening instrument for PTSD. Behav Cog Psychother, 33, 487–498.Google Scholar

Pappas, D. (2006). ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. J Psychoed Assess, 24, 172–178.Google Scholar

Wagner, K. D., Hirschfeld, R., Emslie, G. J., et al. (2006). Validation of the Mood Disorder Questionnaire for bipolar disorders in adolescents. J Clin Psychiatry, 67(5), 827–830.Google Scholar

Chandler, S., Charman, T., Baird, G., et al. (2007). Validation of the social communication questionnaire in a population cohort of children with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry, 46, 1324–1332.CrossRef Google Scholar

Charman, T., Baird, G., Simonoff, E., et al. (2007). Efficacy of three screening instruments in the identification of autistic-spectrum disorders. Br J Psychiatry, 191, 554–559.Google Scholar

Polderman, T. J., Derks, E. M., Hudziak, J. J., et al. (2007). Across the continuum of attention skills: a twin study of the SWAN ADHD rating scale. J Child Psychol Psychiatry, 48, 1080–1087.Google Scholar

Gallant, J., Storch, E. A., Merlo, L. J., et al. (2008). Convergent and discriminant validity of the Children’s Yale-Brown Obsessive Compulsive Scale-symptom checklist. J Anxiety Disord, 22, 1369–1376.Google Scholar

Kaminer, Y. (2008). The teen addiction severity index around the globe: the tower of Babel revisited. Subst Abuse, 29, 89–94.Google Scholar

Lanktree, C. B., Gilbert, A. M., Briere, J., et al. (2008). Multi-informant assessment of maltreated children: convergent and discriminant validity of the TSCC and TSCYC. Child Abuse Negl, 32, 621–625.Google Scholar

Winters, K. C., Kaminer, Y. (2008). Screening and assessing adolescent substance use disorders in clinical populations. J Am Acad Child Adolesc Psychiatry, 47, 740.Google Scholar

Mayes, S. D., Calhoun, S. L., Murray, M. J., et al. (2009). Comparison of scores on the Checklist for Autism Spectrum Disorder, Childhood Autism Rating Scale, and Gilliam Asperger’s Disorder Scale for children with low functioning autism, high functioning autism, Asperger’s disorder, ADHD, and typical development. J Aut Dev Disord, 39, 1682–1693.Google Scholar

Nakamura, B. J., Ebesutani, C., Bernstein, A., et al. (2009). A psychometric analysis of the child behavior checklist DSM-oriented scales. J Psychopathol Behav Assess, 31, 178–189.Google Scholar

Posserud, M-B., Lundervold, A. J., Gillberg, C. (2009). Validation of the autism spectrum screening questionnaire in a total population sample. J Aut Dev Disord, 39, 126–134.Google Scholar

Chlebowski, C., Green, J. A., Barton, M. L., et al. (2010). Using the childhood autism rating scale to diagnose autism spectrum disorders. J Aut Dev Disord, 40, 787–799.Google Scholar

Reynolds, C. R. (2010). Behavior assessment system for children. The Corsini Encyclopedia of Psychology, 1–2.Google Scholar

Becker, S. P., Langberg, J. M., Vaughn, A. J., et al. (2012). Clinical utility of the Vanderbilt ADHD diagnostic parent rating scale comorbidity screening scales. J Dev Behav Pediatr, 33, 221.Google Scholar

Fux, L., Walger, P., Schimmelmann, B. G., et al. (2013). The schizophrenia proneness instrument, child and youth version (SPI-CY): practicability and discriminative validity. Schizophr Res, 146, 69–78.Google Scholar

Martinez, W., Polo, A. J., Zelic, K. J. (2014). Symptom variation on the Trauma Symptom Checklist for Children: a within-scale meta-analytic review. J Traumatic Stress, 27, 655–663.Google Scholar

Stucky, B. D., Edelen, M. O., Ramchand, R. (2014). A psychometric assessment of the GAIN General Individual Severity Scale (GAIN-GISS) and Short Screeners (GAIN-SS) among adolescents in outpatient treatment programs. J Subst Abuse Treat, 46, 165–173.Google Scholar

Sparrow, S., Cicchetti, D. V., Saulnier, C. A. (2016). Vineland adaptive behavior scales (Vineland-3). Antonio: Psychological Corporation.Google Scholar

Pagsberg, A. K., Tarp, S., Glintborg, D., et al. (2017). Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry, 56, 191–202.Google Scholar

Craddock, K. E., Zhou, X., Liu, S., et al. (2018). Symptom dimensions and subgroups in childhood-onset schizophrenia. Schizophr Res, 197, 71–77.Google Scholar

Doric, A., Stevanovic, D., Stupar, D., et al. (2019). UCLA PTSD reaction index for DSM-5 (PTSD-RI-5): a psychometric study of adolescents sampled from communities in eleven countries. Eur J Psychotraumatology, 10, 1605282.Google Scholar

Child Mind Institute. (2017). Children’s Mental Health Report. Available from: https://childmind.org/report/2017-childrens-mental-health-report (last accessed November 3, 2020).Google Scholar

Galynker, I., Ieronimo, C., Perez-Acquino, A., et al. (1996). Panic attacks with psychotic features. J Clin Psychiatry, 57, 402–406.Google Scholar

Schäfer, I., Fisher, H. L. (2011). Childhood trauma and psychosis – what is the evidence? Dialogues Clin Neurosci, 13, 360.Google Scholar

Rodowski, M. F., Cagande, C. C., Riddle, M. A. (2008). Childhood obsessive-compulsive disorder presenting as schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol, 18, 395–401.Google Scholar

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders. Arlington: American Psychiatric Association, p. 81.Google Scholar

Mullin, A., Gokhale, A., Moreno-De-Luca, A., et al. (2013). Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes. Transl Psychiatry, 3, e329–e329.Google Scholar

Landa, R. J., Gross, A. L., Stuart, E. A., et al. (2013). Developmental trajectories in children with and without autism spectrum disorders: the first 3 years. Child Dev, 84, 429–442.Google Scholar

McNamara, D. (2012). Genetic microarrays grow for neurodevelopmental diagnosis. Available from: www.mdedge.com/clinicalneurologynews/article/52657/neurology/genetic-microarrays-grow-neurodevelopmental-diagnosis (last accessed November 3, 2020).Google Scholar

Fluyau, D., Mitra, P., Lorthe, K. (2019). Antipsychotics for amphetamine psychosis. A systematic review. Front Psychiatry, 10, 740.Google Scholar

Cheng, W-J., Chen, C-H., Chen, C-K., et al. (2018). Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res, 199, 313–318.Google Scholar

American Addiction Centers. (2019). Dextromethorphan abuse. Available from: www.drugabuse.com/dextromethorphan (last accessed November 3, 2020).Google Scholar

Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 884–889.Google Scholar

National Institute on Drug Abuse. (2019). Hallucinogens Drug Facts. Available from: www.drugabuse.gov/publications/drugfacts/hallucinogens (last accessed November 3, 2020).Google Scholar

National Institute on Drug Abuse. (2019). Marijuana Drug Facts. Available from: http://www.drugabuse.gov/publications/drugfacts/marijuana (last accessed November 3, 2020).Google Scholar

National Institute on Drug Abuse. (2018). Synthetic Cannabinoids Drug Facts. Avavilable from: http://www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids-k2spice (last accessed November 3, 2020).Google Scholar

National Institute on Drug Abuse. (2018). Synthetic Cathinones Drug Facts. Available from: http://www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-bath-salts (last accessed November 3, 2020).Google Scholar

Fohrman, D. A., Stein, M. T. (2006). Psychosis: 6 steps rule out medical causes in kids. Curr Psychiatr, 5, 35–47.Google Scholar

Stevens, J. R., Prince, J. B., Prager, L. M., et al. (2014). Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management. Prim Care Companion CNS Disord, 16, PCC.13f01514.Google Scholar

Lowenthal, E. D., Cruz, N., Yin, D. (2010). Neurologic and psychiatric manifestations of pediatric HIV infection. HIV Curriculum for the Health Professional, 194–205.Google Scholar

Ramsey, D., Muskin, P. R. (2013). Vitamin deficiencies and mental health: how are they linked. Curr Psychiatr, 12, 37–43.Google Scholar

Firth, J., Carney, R., Stubbs, B., et al. (2018). Nutritional deficiencies and clinical correlates in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull, 44, 1275–1292.Google Scholar

American Academy of Child and Adolescent Psychiatry. (2011). Practice parameters for the use of atypical antipsychotics medication in children and adolescents. Available from: https://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf Google Scholar

Werry, J. S., Weiss, G., Douglas, V., et al. (1966). Studies on the hyperactive child: III. The effect of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry, 5, 292–312.Google Scholar

Engelhardt, D. M., Polizos, P., Waizer, J., et al. (1973). A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J Aut Child Schizophr, 3, 128–137.Google Scholar

Pool, D., Bloom, W., Mielke, D., et al. (1976). A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Therapeut Res, 19(1), 99–104.Google Scholar

Spencer, E. K., Kafantaris, V., Padron-Gayol, M. V., et al. (1992). Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull, 28(2), 183–186.Google Scholar

Kumra, S., Frazier, J. A., Jacobsen, L. K., et al. (1996). Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry, 53, 1090–1097.Google Scholar

Woods, S. W., Breier, A., Zipursky, R. B., et al. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453–464.Google Scholar

Sikich, L., Hamer, R. M., Bashford, R. A., et al. (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29, 133–145.Google Scholar

McGlashan, T. H., Zipursky, R. B., Perkins, D., et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry, 163, 790–799.Google Scholar

Shaw, P., Sporn, A., Gogtay, N., et al. (2006). Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry, 63, 721–730.Google Scholar

Berger, G. E., Proffitt, T-M., McConchie, M., et al. (2008). Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry, 69, 1702–1714.Google Scholar

Findling, R. L., Robb, A., Nyilas, M., et al. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry, 165, 1432–1441.Google Scholar

Sikich, L., Frazier, J. A., McClellan, J., et al. (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry, 165, 1420–1431.Google Scholar

Haas, M., Unis, A. S., Armenteros, J., et al. (2009). A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol, 19, 611–621.Google Scholar

Kryzhanovskaya, L., Schulz, S. C., Mcdougle, C., et al. (2009). Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 48, 60–70.Google Scholar

Findling, R. L., Johnson, J. L., McClellan, J., et al. (2010). Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry, 49, 583–594.Google Scholar

Singh, J., Robb, A., Vijapurkar, U., et al. (2011). A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biological Psychiatry, 70, 1179–1187.CrossRef Google Scholar PubMed

Findling, R. L., McKenna, K., Earley, W. R., et al. (2012). Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol, 22, 327–342.Google Scholar

Savitz, A. J., Lane, R., Nuamah, I., et al. (2015). Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry, 54, 126–137. e121.Google Scholar

Goldman, R., Loebel, A., Cucchiaro, J., et al. (2017). Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. J Child Adolesc Psychopharmacol, 27, 516–525.Google Scholar

Lytle, S., McVoy, M., Sajatovic, M. (2017). Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol, 27, 2–9.Google Scholar

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar

Stahl, S. M. (2019). Stahl’s Essential Psychopharmacology: Prescriber’s Guide, Children and Adolescents. New York: Cambridge University Press.Google Scholar

Stevens, J. R., Prince, J. B. (2012). Schooling students with psychotic disorders. Child Adolesc Psychiatr Clin N Am, 21(1), 187–200.Google Scholar

Xia, J., Merinder, L. B., Belgamwar, M. R. (2011). Psychoeducation for schizophrenia. Cochrane Database Syst Rev, 2011(6), CD002831.Google Scholar

Turkington, D., Kingdon, D., Turner, T. (2002). Effectiveness of a brief cognitive–behavioural therapy intervention in the treatment of schizophrenia. Br J Psychiatry, 180, 523–527.Google Scholar

McGorry, P. D., Yung, A. R., Phillips, L. J., et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry, 59, 921–928.Google Scholar

Wykes, T., Newton, E., Landau, S., et al. (2007). Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res, 94, 221–230.Google Scholar

Lee, R., Redoblado-Hodge, M., Naismith, S., et al. (2013). Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. Psychol Med, 43, 1161–1173.Google Scholar

Kennedy, S. H., Milev, R., Giacobbe, P., et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord, 117 Suppl. 1, S44–53.Google Scholar

Poublon, N. A., Haagh, M., et al. (2011). The efficacy of ECT in the treatment of schizophrenia. A systematic review. Erasmus J Med, 2(1), 48.Google Scholar

Brenner, H. D., Dencker, S. J., Goldstein, M. J., et al. (1990). Defining treatment refractoriness in schizophrenia. Schizophr Bull, 16, 551–561.Google Scholar

Conley, R. R., Buchanan, R. W. (1997). Evaluation of treatment-resistant schizophrenia. Schizophr Bull, 23, 663–674.Google Scholar

Meltzer, H. Y. (1997). Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin, 14, 1–20.Google Scholar

Meltzer, H. Y. (1992). Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull, 18, 515–542.Google Scholar

Remington, G., Saha, A., Chong, S. A., et al. (2005). Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs, 19, 843–872.Google Scholar

Tranulis, C., Mouaffak, F., Chouchana, L., et al. (2006). Somatic augmentation strategies in clozapine resistance – what facts? Clin Neuropharmacol, 29, 34–44.Google Scholar

Cipriani, A., Boso, M., Barbui, C. (2009). Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev, 8(3), CD006324.Google Scholar

Porcelli, S., Balzarro, B., Serretti, A. (2012). Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol, 22, 165–182.Google Scholar

Taylor, D. M., Smith, L., Gee, S. H., et al. (2012). Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand, 125, 15–24.Google Scholar

American Psychiatric Association. (2001). The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association. Washington, D.C.Google Scholar

Tharyan, P., Adams, C. E. (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev, 18(2), CD000076.Google Scholar

Pompili, M., Lester, D., Dominici, G., et al. (2013). Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res, 146, 1–9.Google Scholar

Gazdag, G., Kocsis-Ficzere, N., Tolna, J. (2006). The augmentation of clozapine treatment with electroconvulsive therapy. Ideggyogy Sz, 59, 261–267.Google Scholar

Small, J. G., Milstein, V., Klapper, M., Kellams, J.J., Small, I.F. (1982). ECT combined with neuroleptics in the treatment of schizophrenia. Psychopharmacol Bull, 18(2), 34–35.Google Scholar

Abraham, K. R., Kulhara, P. (1987). The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. Br J Psychiatry, 151, 152–155.Google Scholar

Petrides, G., Malur, C., Braga, R. J., et al. (2015). Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry, 172, 52–58.Google Scholar

Grover, S., Hazari, N., Kate, N. (2015). Combined use of clozapine and ECT: a review. Acta Neuropsychiatr, 27, 131–142.Google Scholar

Leucht, S., Tardy, M., Komossa, K., et al. (2012). Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev, 2012, CD008016.Google Scholar

Zipursky, R. B., Menezes, N. M., Streiner, D. L. (2014). Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res, 152, 408–414.Google Scholar

Sackeim, H. A., Haskett, R. F., Mulsant, B. H., et al. (2001). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA, 285, 1299–1307.Google Scholar

Ward, H. B., Szabo, S. T., Rakesh, G. (2018). Maintenance ECT in schizophrenia: a systematic review. Psychiatry Res, 264, 131–142.Google Scholar

Chanpattana, W., Chakrabhand, M. L., Sackeim, H. A., et al. (1999). ECT in treatment-resistant schizophrenia: a controlled study. Journal of ECT, 15(3), 178–192.Google Scholar

Yang, Y., Cheng, X., Xu, Q., et al. (2016). The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arq Neuropsiquiatr, 10, 823–828.Google Scholar

Maley, C. T., Becker, J. E., Shultz, E. K. B. (2019). Electroconvulsive therapy and other neuromodulation techniques for the treatment of psychosis. Child Adolesc Psychiatr Clin N Am, 28, 91–100.Google Scholar

Freitas, C., Fregni, F., Pascual-Leone, A. (2009). Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res, 108(1–3), 11–24.Google Scholar

Slotema, C. W., Blom, J. D., van Lutterveld, R., et al. (2014). Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biol Psychiatry, 76, 101–110.Google Scholar

Nieuwdorp, W., Koops, S., Somers, M., et al. (2015). Transcranial magnetic stimulation, transcranial direct current stimulation and electroconvulsive therapy for medication-resistant psychosis of schizophrenia. Curr Opin Psychiatry, 28, 222–228.Google Scholar

Dlabac-de Lange, J. J., Knegtering, R., Aleman, A. (2010). Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry, 71, 411–418.Google Scholar

Prikryl, R., Kucerova, H. (2013). Can repetitive transcranial magnetic stimulation be considered an effective treatment option for negative symptoms of schizophrenia? Journal of ECT, 29(1), 67–74.Google Scholar

Shi, C., Yu, X., Cheung, E., et al. (2014). Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res, 215(3), 505–513.Google Scholar

Zhou, K., Tang, Y., Song, Z., et al. (2019). Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. Neuropsychiatr Dis Treat, 15, 1141–1150.Google Scholar

Marzouk, T., Winkelbeiner, S., Azizi, H., et al. (2019). Transcranial magnetic stimulation for positive symptoms in schizophrenia: a systematic review. Neuropsychobiology, 10, 1–13.Google Scholar

Arumugham, S. S., Thirthalli, J., Andrade, C. (2016). Efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia. Expert Rev Clin Pharmacol, 9, 1245–1252.Google Scholar

Narayana, S., Papanicolaou, A. C., McGregor, A., et al. (2015). Clinical applications of transcranial magnetic stimulation in pediatric neurology. J Child Neurol, 30, 1111–1124.Google Scholar

Brunelin, J., Mondino, M., Gassab, L., et al. (2012). Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry, 169, 719–724.CrossRef Google Scholar PubMed

Mervis, J. E., Capizzi, R. J., Boroda, E., et al. (2017). Transcranial direct current stimulation over the dorsolateral prefrontal cortex in schizophrenia: a quantitative review of cognitive outcomes. Front Hum Neurosci, 11, 44.Google Scholar

Fitzgerald, P. B., McQueen, S., Daskalakis, Z. J., et al. (2014). A negative pilot study of daily bimodal transcranial direct current stimulation in schizophrenia. Brain Stimul, 7, 813–816.Google Scholar

Frohlich, F., Burrello, T. N., Mellin, J. M., et al. (2016). Exploratory study of once-daily transcranial direct current stimulation (tDCS) as a treatment for auditory hallucinations in schizophrenia. Eur Psychiatry, 33, 54–60.Google Scholar

Narita, Z., Stickley, A., DeVylder, J., et al. (2019). Effect of multi-session prefrontal transcranial direct current stimulation on cognition in schizophrenia: a systematic review and meta-analysis. Schizophr Res, 216, 367–373.Google Scholar

Hasan, A., Wolff-Menzler, C., Pfeiffer, S., et al. (2015). Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. Eur Arch Psychiatry Clin Neurosci, 265, 589–600.Google Scholar

Perez, S. M., Carreno, F. R., Frazer, A., et al. (2014). Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia. J Neurosci, 34, 9261–9267.Google Scholar

Smucny, J., Visani, A., Tregellas, J. R. (2015). Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia? Front Psychiatry, 6, 43.Google Scholar

Blumer, D., Davies, K., Alexander, A., et al. (2001). Major psychiatric disorders subsequent to treating epilepsy by vagus nerve stimulation. Epilepsy Behav, 2, 466–472.Google Scholar

Keller, S., Lichtenberg, P. (2008). Psychotic exacerbation in a patient with seizure disorder treated with vagus nerve stimulation. Isr Med Assoc J, 10, 550–551.Google Scholar

Mikell, C. B., McKhann, G. M., Segal, S., et al. (2009). The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg, 87, 256–265.Google Scholar

Kuhn, J., Bodatsch, M., Sturm, V., et al. (2014). Deep brain stimulation in schizophrenia. Act Nerv Super, 3, 69–78.Google Scholar

Gault, J. M., Davis, R., Cascella, N. G., et al. (2018). Approaches to neuromodulation for schizophrenia. J Neurol Neurosurg Psychiatry, 89, 777–787.Google Scholar

Schermer, M. (2011). Ethical issues in deep brain stimulation. Front Integr Neurosci, 5, 17.Google Scholar

Benazzi, F. (2006). Various forms of depression. Dialogues Clin Neurosci, 8, 151–161.Google Scholar

Aichhorn, W., Stelzig-Schoeler, R., Geretsegger, C., et al. (2007). Bright light therapy for negative symptoms in schizophrenia: a pilot study. J Clin Psychiatry, 68, 1146.Google Scholar

Roopram, S. M., Burger, A. M., van Dijk, D. A., et al. (2016). A pilot study of bright light therapy in schizophrenia. Psychiatry Res, 245, 317–320.Google Scholar

Myles, N., Newall, H. D., Curtis, J., et al. (2012). Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry, 73, 468–475.Google Scholar

Myles, H., Myles, N., Large, M. (2016). Cannabis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use. Aust N Z J Psychiatry, 50, 208–219.Google Scholar

Hasan, A., von Keller, R., Friemel, C. M., et al. (2019). Cannabis use and psychosis: a review of reviews. Eur Arch Psychiatry Clin Neurosci, 270(4), 403–412.Google Scholar

Callaghan, R. C., Cunningham, J. K., Allebeck, P., et al. (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry, 169, 389–396.Google Scholar

Substance Abuse and Mental Health Services Administration. (2019). First-episode psychosis and co-occurring substance use disorders. Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Publication no. PEP19-PL-Guide-3.Google Scholar

Swartz, M. S., Wagner, H. R., Swanson, J. W., et al. (2006). Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis, 194, 164–172.Google Scholar

Kerfoot, K. E., Rosenheck, R. A., Petrakis, I. L., et al. (2011). Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res, 132, 177–182.Google Scholar

Fazel, S., Långström, N., Hjern, A., et al. (2009). Schizophrenia, substance abuse, and violent crime. JAMA, 301, 2016–2023.Google Scholar

Lamsma, J., Cahn, W., Fazel, S. (2019). Use of illicit substances and violent behaviour in psychotic disorders: two nationwide case-control studies and meta-analyses. Psychol Med, 50(12), 2028–2033.Google Scholar

Jaffee, W. B., Trucco, E., Levy, S., et al. (2007). Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat, 33, 33–42.Google Scholar

DiClemente, C. C., Nidecker, M., Bellack, A. S. (2008). Motivation and the stages of change among individuals with severe mental illness and substance abuse disorders. J Subst Abuse Treat, 34, 25–35.Google Scholar

Ziedonis, D. M., Smelson, D., Rosenthal, R. N., et al. (2005). Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract, 11, 315.Google Scholar

McDonell, M. G., Srebnik, D., Angelo, F., et al. (2013). Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiatry, 170, 94–101.Google Scholar

McPherson, S., Orr, M., Lederhos, C., et al. (2018). Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence. Behav Pharmacol, 29, 370–374.Google Scholar

Green, A. I., Tohen, M. F., Hamer, R. M., et al. (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res, 66, 125–135.Google Scholar

Bennett, M. E., Bradshaw, K. R., Catalano, L. T. (2017). Treatment of substance use disorders in schizophrenia. Am J Drug Alcohol Abuse, 43, 377–390.Google Scholar

Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., et al. (2012). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. FOCUS, 10, 194–216.Google Scholar

Martins, S. S., Gorelick, D. A. (2011). Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend, 119, 28–36.Google Scholar

Wildgust, H. J., Beary, M. (2010). Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol, 24, 37–50.Google Scholar

Cather, C., Pachas, G. N., Cieslak, K. M., et al. (2017). Achieving smoking cessation in individuals with schizophrenia: special considerations. CNS Drugs, 31, 471–481.Google Scholar

Kalkhoran, S., Glantz, S. A. (2016). E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med, 4, 116–128.Google Scholar

Tsuda, Y., Saruwatari, J., Yasui-Furukori, N. (2014). Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open, 4, e004216.Google Scholar

Meyer, J. M. (2001). Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol, 21, 569–574.Google Scholar

Robertson, A. G., Easter, M. M., Lin, H., et al. (2018). Medication-assisted treatment for alcohol-dependent adults with serious mental illness and criminal justice involvement: effects on treatment utilization and outcomes. Am J Psychiatry, 175, 665–673.Google Scholar

Robertson, A. G., Easter, M. M., Lin, H. J., et al. (2018). Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness. J Subst Abuse Treat, 86, 17–25.Google Scholar

Spencer, C., Castle, D., Michie, P. T. (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull, 28, 233–247.Google Scholar

Toftdahl, N. G., Nordentoft, M., Hjorthoj, C. (2016). The effect of changes in cannabis exposure on psychotic symptoms in patients with comorbid cannabis use disorder. J Dual Diagn, 12, 129–136.Google Scholar

Green, A. I., Burgess, E. S., Dawson, R., et al. (2003). Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res, 60, 81–85.Google Scholar

Chan, B., Freeman, M., Kondo, K., et al. (2019). Pharmacotherapy for methamphetamine/amphetamine use disorder – a systematic review and meta-analysis. Addiction, 114, 2122–2136.Google Scholar

Chan, B., Kondo, K., Freeman, M., et al. (2019). Pharmacotherapy for cocaine use disorder – a systematic review and meta-analysis. J Gen Intern Med, 34, 2858–2873.Google Scholar

Sena, S. F., Kazimi, S., Wu, A. H. (2002). False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin Chem, 48, 676–677.Google Scholar

Heit, H. A., Gourlay, D. L. (2004). Urine drug testing in pain medicine. J Pain Symptom Manage, 27, 260–267.Google Scholar

Moeller, K. E., Lee, K. C., Kissack, J. C. (2008). Urine drug screening: practical guide for clinicians. Mayo Clin Proc, 83(1), 66–76.Google Scholar

Nasky, K. M., Cowan, G. L., Knittel, D. R. (2009). False-positive urine screening for benzodiazepines: an association with sertraline? A two-year retrospective chart analysis. Psychiatry (Edgmont), 6, 36.Google Scholar

Reisfield, G. M., Goldberger, B. A., Bertholf, R. L. (2009). “False-positive” and “false-negative” test results in clinical urine drug testing. Bioanalysis, 1, 937–952.Google Scholar

Mikel, C., Pesce, A. J., Rosenthal, M., et al. (2012). Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety. Clin Chim Acta, 413, 1199–1202.Google Scholar

Saitman, A., Park, H-D., Fitzgerald, R. L. (2014). False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol, 38, 387–396.Google Scholar

Bohn, M., Babor, T., Kranzler, H. (1991). Validity of the Drug Abuse Screening Test (DAST-10) in inpatient substance abusers. Problems of Drug Dependence, 119, 233–235.Google Scholar

Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., et al. (1991). The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict, 86, 1119–1127.Google Scholar

Saunders, J. B., Aasland, O. G., Babor, T. F., et al. (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption – II. Addiction, 88, 791–804.Google Scholar

Bush, K., Kivlahan, D. R., McDonell, M. B., et al. (1998). The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med, 158, 1789–1795.Google Scholar

Knight, J. R., Shrier, L. A., Bravender, T. D., et al. (1999). A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med, 153, 591–596.Google Scholar

Maisto, S. A., Carey, M. P., Carey, K. B., et al. (2000). Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness. Psychol Assess, 12, 186–192.Google Scholar

Knight, J. R., Sherritt, L., Shrier, L. A., et al. (2002). Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med, 156, 607–614.Google Scholar

Bradley, K. A., DeBenedetti, A. F., Volk, R. J., et al. (2007). AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res, 31, 1208–1217.Google Scholar

Pearsall, R., Smith, D. J., Geddes, J. R. (2019). Pharmacological and behavioural interventions to promote smoking cessation in adults with schizophrenia and bipolar disorders: a systematic review and meta-analysis of randomised trials. BMJ Open, 9, e027389.Google Scholar

Tsoi, D. T-Y., Porwal, M., Webster, A. C. (2010). Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry, 196, 346–353.Google Scholar

Evins, A. E., Cather, C., Pratt, S. A., et al. (2014). Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA, 311, 145–154.Google Scholar

Ralevski, E., O’Brien, E., Jane, J. S., et al. (2011). Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Dual Diagn, 7, 64–73.Google Scholar

Paz, R. D., Tardito, S., Atzori, M., et al. (2008). Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol, 18, 773–786.Google Scholar

Forest Pharmaceuticals, I. (2004). Highlights of prescribing information for acamprosate sodium. New York.Google Scholar

Petrakis, I. L., Nich, C., Ralevski, E. (2006). Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull, 32, 644–654.Google Scholar

Siever, L. J. (2008). Neurobiology of aggression and violence. Am J Psychiatry, 165, 429–442.Google Scholar

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.Google Scholar

Rosenbloom, M. H., Schmahmann, J. D., Price, B. H. (2012). The functional neuroanatomy of decision-making. J Neuropsychiatry Clin Neurosci, 24, 266–277.Google Scholar

Nash, R. P., Weinberg, M. S., Laughon, S. L., et al. (2019). Acute pharmacological management of behavioral and emotional dysregulation following a traumatic brain injury: a systematic review of the literature. Psychosomatics, 60, 139–152.Google Scholar

Hicks, A. J., Clay, F. J., Hopwood, M., et al. (2019). The efficacy and harms of pharmacological interventions for aggression after traumatic brain injury: a systematic review. Front Neurol, 10, 1169.Google Scholar

Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., et al. (2013). Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol, 149, 1025–1032.Google Scholar

Hammond, F. M., Bickett, A. K., Norton, J. H., et al. (2014). Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil, 29, 391–399.Google Scholar

Sami, M. B., Faruqui, R. (2015). The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke. Acta Neuropsychiatr, 27, 317–326.Google Scholar

Hammond, F. M., Malec, J. F., Zafonte, R. D., et al. (2017). Potential impact of amantadine on aggression in chronic traumatic brain injury. J Head Trauma Rehabil, 32, 308–318.Google Scholar

Hammond, F. M., Sherer, M., Malec, J. F., et al. (2015). Amantadine effect on perceptions of irritability after traumatic brain injury: results of the amantadine irritability multisite study. J Neurotrauma, 32, 1230–1238.Google Scholar

Cummings, J., Lai, T. J., Hemrungrojn, S., et al. (2016). Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther, 22, 159–166.Google Scholar

Gareri, P., Putignano, D., Castagna, A., et al. (2014). Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s disease: the MEMAGE study. J Alzheimers Dis, 41, 633–640.Google Scholar

Seitz, D. P., Adunuri, N., Gill, S. S., et al. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev, 2011, CD008191.Google Scholar

Maust, D. T., Kim, H. M., Seyfried, L. S., et al. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry, 72, 438–445.Google Scholar

Deardorff, W. J., Grossberg, G. T. (2019). Behavioral and psychological symptoms in Alzheimer’s dementia and vascular dementia. Handb Clin Neurol, 165, 5–32.Google Scholar

Reus, V. I., Fochtmann, L. J., Eyler, A. E., et al. (2016). The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry, 173, 543–546.Google Scholar

Devanand, D. P., Mintzer, J., Schultz, S., et al. (2012). The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry, 20, 362–373.Google Scholar

Gallagher, D., Herrmann, N. (2014). Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs, 74, 1747–1755.Google Scholar

Suzuki, H., Gen, K. (2015). Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer’s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics, 15, 32–37.Google Scholar

Tampi, R. R., Tampi, D. J. (2014). Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen, 29, 565–574.Google Scholar

Plantier, D., Luaute, J., Group, S. (2016). Drugs for behavior disorders after traumatic brain injury: systematic review and expert consensus leading to French recommendations for good practice. Ann Phys Rehabil Med, 59, 42–57.Google Scholar

Keszycki, R. M., Fisher, D. W., Dong, H. (2019). The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer’s disease: current management and future directions. Front Pharmacol, 10, 1109.Google Scholar

Book contents

Part I - Treatment Strategies

Summary

Access options

Subscription

Individual access

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Book contents

Part I - Treatment Strategies

Summary

Access options

Subscription

Individual access

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive